Revolution Medicines, Inc.
RVMDW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 16 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $104.3M in total; no superinvestor holds it.
Other share classesRVMD
13F holders, Q2 2026
Institutional positions in Revolution Medicines, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- −1 vs. Q1 2026
- Shares held
- 10.1M
- +28.9K (+0.3%) vs. Q1 2026
- Total value
- $104.3M
- +$86.2M (+476.2%) vs. Q1 2026
- New holders
- 3
- 3 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RVMDW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $104.3M |
| Q1 2026 | 23 | $18.1M |
| Q4 2025 | 24 | $8.31M |
| Q3 2025 | 22 | $2.46M |
| Q2 2025 | 23 | $2.20M |
| Q1 2025 | 24 | $316.0K |
| Q4 2024 | 24 | $1.71M |
| Q3 2024 | 25 | $1.04M |
| Q2 2024 | 25 | $953.6K |
| Q1 2024 | 24 | $1.50M |
| Q4 2023 | 22 | $1.89M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Revolution Medicines, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| LMR Partners LLP | 5,066,598 | $47.5M | 0.35% | +1,228,574+32.0% | Added |
| D. E. Shaw & Co., Inc. | 1,580,345 | $14.9M | 0.01% | 00.0% | Unchanged |
| Sculptor Capital LP | 709,670 | $6.66M | 0.07% | −249,152−26.0% | Reduced |
| CSS LLC | 78,367 | $6.61M | 0.29% | +60,862+347.7% | Added |
| Price T Rowe Associates Inc | 579,550 | $5.45M | 0.00% | 00.0% | Unchanged |
| Caption Management, LLC | 517,685 | $4.86M | 0.17% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 500,000 | $4.69M | 0.01% | 00.0% | Unchanged |
| Rangeley Capital, LLC | 25,000 | $4.68M | 4.35% | +25,000 | New |
| Perceptive Advisors LLC | 250,000 | $2.34M | 0.04% | 00.0% | Unchanged |
| Bleichroeder LP | 200,000 | $1.88M | 0.34% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 154,544 | $1.45M | 0.02% | −16,154−9.5% | Reduced |
| Farallon Capital Management, L.L.C. | 120,085 | $1.13M | 0.01% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 94,797 | $889.2K | 0.26% | +94,797 | New |
| Weiss Asset Management LP | 73,640 | $692.2K | 0.01% | 00.0% | Unchanged |
| TD Asset Management Inc | 40,636 | $382.0K | 0.00% | 00.0% | Unchanged |
| Driehaus Capital Management LLC | 20,000 | $188.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,461 | $23.1K | 0.00% | +1,575+177.8% | Added |
| Morgan Stanley | 2,216 | $20.8K | 0.00% | 00.0% | Unchanged |
| DLK Investment Management, LLC | 77,000 | $7.86K | 0.00% | +77,000 | New |
| TD Waterhouse Canada Inc. | 448 | $4.12K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 200 | $2.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 60 | $562 | 0.00% | −30−33.3% | Reduced |
| Aristeia Capital LLC | 0 | $0 | 0.00% | −583,615−100.0% | Sold out |
| Lunate Capital Ltd | 0 | $0 | 0.00% | −450,000−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −150,000−100.0% | Sold out |
| Toronto Dominion Bank | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |